💊FDA PHARMA TODAY
Roche’s Rituxan Gets Priority Review for Label Expansion
Roche Group’s RHHBY member Genentech announced that the FDA accepted Supplemental Biologics License Application (sBLA) and granted Priority Review for the label expansion of the company’s leukemia drug Rituxan (rituximab).
The company is seeking to get Rituxan approved for the treatment of pemphigus vulgaris, which is a life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.
February 14, 2018 Zacks.com